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Abstract
Systemic chemotherapy has been relatively ineffective in the treatment of malignant brain tumors
even though systemic chemotherapy drugs are small molecules that can readily extravasate across
the porous blood-brain tumor barrier of malignant brain tumor microvasculature. Small molecule
systemic chemotherapy drugs maintain peak blood concentrations for only minutes, and therefore,
do not accumulate to therapeutic concentrations within individual brain tumor cells. The
physiologic upper limit of pore size in the blood-brain tumor barrier of malignant brain tumor
microvasculature is approximately 12 nanometers. Spherical nanoparticles ranging between 7 nm
and 10 nm in diameter maintain peak blood concentrations for several hours and are sufficiently
smaller than the 12 nm physiologic upper limit of pore size in the blood-brain tumor barrier to
accumulate to therapeutic concentrations within individual brain tumor cells. Therefore,
nanoparticles bearing chemotherapy that are within the 7 to 10 nm size range can be used to
deliver therapeutic concentrations of small molecule chemotherapy drugs across the blood-brain
tumor barrier into individual brain tumor cells. The initial therapeutic efficacy of the Gd-G5-
doxorubicin dendrimer, an imageable nanoparticle bearing chemotherapy within the 7 to 10 nm
size range, has been demonstrated in the orthotopic RG-2 rodent malignant glioma model. Herein
I discuss this novel strategy to improve the effectiveness of systemic chemotherapy for the
treatment of malignant brain tumors and the therapeutic implications thereof.
Background
Malignant brain tumors consist of high-grade primary
brain tumors such as malignant gliomas[1], and meta-
static lesions to the brain from peripheral cancers such as
lung, breast, renal, gastrointestinal tract, and
melanoma[2,3]. Glioblastoma, the highest grade of
malignant glioma, is the most common high-grade pri-
mary brain tumor in adults[4,5]. Overall, metastatic brain
tumors are the most common brain tumors in adults, as
10% to 20% of patients with a malignant peripheral
tumor develop brain metastases[2,3,6]. Even though
malignant gliomas are generally treated with a combina-
tion of surgery, radiotherapy and systemic chemother-
apy[7,8], and metastatic brain tumors with a combination
of surgery and radiotherapy [9-11], the overall long-term
prognosis of patients with these tumors, whether primary
or metastatic, remains poor. Patient median survival times
typically range between 3 and 16 months [12-16], and the
percentage of patients alive at 5 years ranges between 3%
and 10%[12,13,16,17]. In the treatment of both malig-
nant gliomas and metastatic brain tumors, surgery and
radiotherapy are more effective when used in combina-
tion[7-11,18-20]. In the treatment of malignant gliomas,
there some minimal additional benefit of systemic chem-
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otherapy[8,15,20-27]; and in the treatment of metastatic
brain tumors, it remains unclear as to if there is any addi-
tional benefit of systemic chemotherapy[9,10,28-31].
Systemic chemotherapy consists of small molecule chem-
otherapy drugs[8,32] that are drugs of molecular weights
(MW) less than 1 kDa and diameters less than 1 to 2 nm.
These small molecule chemotherapy drugs include tradi-
tional drugs that target the cell cycle, for example, DNA
alkylating drugs, and newer investigational drugs that tar-
get cell surface receptors and associated pathways, for
example, tyrosine kinase inhibitors[8,32]. The ineffective-
ness of these chemotherapy drugs in treating malignant
brain tumors has been attributed to the blood-brain bar-
rier (BBB) being a significant impediment to the transvas-
cular extravasation of drug fraction across the barrier into
the extravascular compartment of tumor tissue[29,33-35].
However, the pathologic BBB of malignant brain tumor
microvasculature, also known as the blood-brain tumor
barrier (BBTB), is porous[36,37]. Contrast enhancement
of malignant brain tumors on MRI is due to the transvas-
cular extravasation of Gd-DTPA (Magnevist, MW 0.938
kDa) across the pores in the BBTB into the extravascular
extracellular compartment of tumor tissue[38,39].
Historical strategies to improve the 
effectiveness of systemic chemotherapy
Historically, two different strategies have been employed
in the effort to improve the effectiveness of small mole-
cule systemic chemotherapy in treating malignant brain
tumors, although neither strategy has been particularly
effective. The first strategy has been to elevate small mole-
cule drug concentrations within the extravascular extracel-
lular compartment of tumor tissue. One approach to this
strategy has been the use of lipophilic small molecule
drugs for increased permeation of drug fraction across
endothelial cells of the BBTB[40,41]. The effectiveness of
this approach has been limited due to drug binding to
plasma proteins[42], in addition to the efflux of a signifi-
cant proportion of extravasated drug fraction back into
systemic circulation by BBTB multi-drug resistance pumps
such as p-glycoprotein[35,43]. Other approaches to this
strategy include the administration of drugs intra-arteri-
ally to maximize first-pass drug delivery across the BBTB
[44-46], and the temporary opening of the junctions
between endothelial cells of the BBTB to enhance the per-
meation of drugs across the BBTB[34,47,48]. The overall
ineffectiveness of these approaches can be attributed to
the fact that there is only a transient elevation in drug con-
centrations within extravascular extracellular compart-
ment of tumor tissue due to the short blood half-life of
small molecule chemotherapy [49-55], which precludes
the accumulation of drug fraction to therapeutic concen-
trations within individual brain tumor cells.
The second strategy has been to increase the blood half-
life of small molecule chemotherapy. One approach to
this strategy has been the intravenous co-administration
of labradimil (RMP-7, Cereport), a metabolically stable
bradykinin B2 receptor agonist, during the intravenous
administration of small molecule chemotherapy drugs
such as carboplatin. Although the co-administration of
labradimil increases the blood half-life of small molecule
chemotherapy drugs [56-59], the increase in drug blood
half-life is temporary[60], which again, precludes the
accumulation of drug fraction to therapeutic concentra-
tions within individual brain tumor cells. Another
approach to this strategy has been the use of continuous
chemotherapy dosing schemes[61,62]. The potential
effectiveness of this approach, however, has been limited
by the systemic toxicity associated with it, which is due to
the non-specific accumulation of small molecule drugs
within normal tissues, as these drugs are small enough to
permeate across endothelial barriers of normal tissue
microvasculature [61-64].
In more recent years, slow sustained-drug release formula-
tions of small molecule chemotherapy drugs have been
developed by the non-covalent attachment of chemother-
apy drugs to polymers or the encapsulation of drugs
within liposomes[65,66]. Such nanoparticle-based drug
release formulations are intravascular free drug reservoirs
with long blood half-lives, since these spherical nanopar-
ticles generally range between 30 nm and 200 nm in
diameter [67-69], and are significantly larger than the
physiologic upper limit of pore size in the BBTB of malig-
nant brain tumor microvasculature. Since nanoparticle-
based drug release formulations remain intravascular
within brain tumor microvasculature, free drug is slowly
released into systemic circulation, and not directly within
individual brain tumor cells. Therefore, nanoparticle-
based slow sustained-drug release formulations of small
molecule chemotherapy drugs that are larger than the 12
nm physiologic upper limit of pore size in the BBTB result
in sub-therapeutic drug concentrations within individual
brain tumor cells, since free drug is not released directly
within individual brain tumor cells [70-72].
Novel strategy to improve the effectiveness of 
systemic chemotherapy
The novel strategy that I propose here to improve the
effectiveness of systemic chemotherapy in the treatment
of malignant brain tumors is based on my two recent
observations[59,73,74]. The first observation being that
spherical nanoparticles smaller than 12 nm in diameter,
but not larger, can extravasate across the porous BBTB of
malignant brain tumor microvasculature[73,74]. The sec-
ond observation being that the subset of nanoparticles
ranging between 7 nm and 10 nm in diameter are of sizesJournal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
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sufficiently smaller than the 12 nm physiologic upper
limit of pore size within the BBTB and maintain peak
blood concentrations for several hours, and therefore, can
accumulate over time to effective concentrations within
individual brain tumor cells[73,74]. Based on these two
observations, spherical nanoparticles ranging between 7
nm and 10 nm in diameter can be used to deliver thera-
peutic concentrations of small molecule chemotherapy
drugs across the BBTB and into individual malignant
brain tumor cells. Since systemically administered nano-
particles within this 7 to 10 nm size range would not
extravasate across the normal BBB of brain microvascula-
ture [73-77] or across the endothelial barriers of most nor-
mal tissue microvasculature[59,63,78,79], these
nanoparticles would extravasate "selectively" across the
porous BBTB of malignant brain tumor microvasculature.
We have recently demonstrated that an imageable nano-
particle bearing chemotherapy within the 7 to 10 nm size
range at delivers therapeutic concentrations of small mol-
ecule chemotherapy across the BBTB into individual brain
tumor cells. This prototype of an imageable nanoparticle
bearing small molecule chemotherapy is a gadolinium
(Gd)-diethyltriaminepentaacetic acid (DTPA) chelated
generation 5 (G5) polyamidoamine (PAMAM) dendrimer
with a proportion of the available terminal amines conju-
gated via pH-sensitive covalent linkages to doxorubicin
(Adriamycin; MW 0.580 kDa), a fluorescent small mole-
cule chemotherapy drug that intercalates with DNA and
inhibits the DNA replication process. The initial therapeu-
tic efficacy of the Gd-G5-doxorubicin dendrimer has been
tested in the orthotopic RG-2 rodent malignant glioma
model. In this rodent glioma model we have found that
one dose of the Gd-G5-doxorubicin dendrimer is signifi-
cantly more effective than one dose of free doxorubicin at
inhibiting the growth of RG-2 gliomas for approximately
24 hours.
The physiologic upper limit of pore size in the 
BBTB of malignant brain tumor 
microvasculature
Simple diffusion of nutrients and metabolites between
tumor cells and pre-existent host tissue microvasculature
is only sufficient to sustain solid tumor growth to a vol-
ume of 1 to 2 mm3[80]. Additional tumor growth requires
the formation of new microvasculature, a process that is
mediated by vascular endothelial growth factor
(VEGF)[81]. The new tumor microvasculature induced by
VEGF is discontinuous due to the presence of anatomic
defects within and between endothelial cells of the tumor
barrier[82,83]. These anatomic defects in the tumor bar-
rier can be several hundred nanometers wide [84-86]. For
this reason, the endothelial barrier of malignant solid
tumor microvasculature is more permeable to the trans-
vascular passage of macromolecules than the endothelial
barriers of normal tissue microvasculature including that
of the kidney glomeruli[83,87]. Even though the ana-
tomic defects within the endothelial barriers of malignant
solid tumor microvasculature are relatively wide [84-86],
we have found that in the physiologic state in vivo there is
a fairly well-defined upper limit of pore size, which is
approximately 12 nm, independent of whether the loca-
tion of the malignant solid tumor is within the brain and
the central nervous system[73,74], or outside of it, in
peripheral tissues[74].
Polyamidoamine (PAMAM) dendrimers functionalized
with gadolinium (Gd)-diethyltriaminepentaacetic acid
(DTPA), a small molecule MRI contrast agent, range in
diameter between 1.5 nm (Gd-DTPA PAMAM dendrimer
generation 1, Gd-G1) and 14 nm (Gd-DTPA PAMAM den-
drimer generation 8, Gd-G8)[73,74]. Since each Gd-DTPA
moiety carries a charge of -2, conjugation of Gd-DTPA to
a significant proportion of the terminal amine groups on
PAMAM dendrimer exterior neutralizes the positively
charged exterior of naked PAMAM dendrimers (Figure 1,
panels A and B). The masses of Gd-G5 through Gd-G8
dendrimer particles are sufficient enough for particle visu-
alization by annular dark-field scanning transmission
electron microscopy (ADF STEM)[73,74,88], and the sizes
of Gd-G7 and Gd-G8 dendrimer particles are large enough
for estimation of particle diameters, which are approxi-
mately 11 nm for Gd-G7 dendrimers and approximately
13 nm for Gd-G8 dendrimers (Figure 1, panel C)[73,74].
Particle transvascular extravasation across the BBTB and
accumulation within the extravascular compartment of
brain tumor tissue has been historically measured with
quantitative autoradiography [89-91], which only pro-
vides information about particle accumulation once per
specimen at post-mortem, or by intravital fluorescence
microscopy[92], which requires that tumors be grown in
dorsal window chambers and provides low-resolution
real-time data. In more recent years, dynamic contrast-
enhanced MRI has been used to visualize the degree of
particle transvascular extravasation across the
BBTB[59,73,93,94], since it is non-invasive and provides
high-resolution real-time data. With dynamic contrast-
enhanced MRI it is possible to measure over time the
degree of Gd-dendrimer extravasation across the BBTB
and accumulation in the extravascular compartment of
tumor tissue. The Gd-dendrimer concentration in tumor
tissue can be estimated by the in vivo measurement of
tumor tissue MRI signal at baseline (T10) and then again
following the intravenous infusion of the Gd-dendrimer
(T1), and the in vitro measurement of the molar relaxivity
(r1) of the Gd-dendrimer, which is the proportionality
constant for conversion of Gd signal to Gd concentra-
tion[73,74,95].Journal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
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We have determined that Gd-G1 through Gd-G7 den-
drimer particles traverse the pores of the BBTB of RG-2
rodent malignant glioma microvasculature and enter the
extravascular compartment of tumor tissue, but that the
Gd-G8 dendrimer particles remain intravascular (Figure 2,
panels A and B)[73,74]. Therefore, the physiologic upper
limit of pore size within the BBTB of malignant brain
tumor microvasculature is approximately 12 nm, since
Gd-G7 dendrimers, being approximately 11 nm in diam-
eter, can extravasate across the BBTB, whereas Gd-G8 den-
drimers, being approximately 13 nm in diameter,
cannot[73,74]. On comparison of the physiologic upper
limit of pore size in the BBTB of small RG-2 glioma micro-
vasculature to that of the BBTB of large RG-2 glioma
microvasculature, we have found that Gd-G1 through Gd-
G6 dendrimers also readily traverse pores within the BBTB
of small RG-2 glioma microvasculature (Figure 2, panel
B)[73]. However, Gd-G7 dendrimers do not readily
extravasate across the BBTB of small RG-2 glioma microv-
asculature (Figure 2, panel B)[73]. This finding is consist-
ent with the likelihood that the physiologic upper limit of
pore size in the BBTB of the microvasculature of early, less
mature and smaller malignant brain tumor colonies is 1
to 2 nanometers lower than that of the BBTB of the micro-
vasculature of late, more mature and larger malignant
brain tumors. Since most small molecule chemotherapy
drugs are less than 1 to 2 nm in diameter, a slightly lower
physiologic upper limit of pore size in the BBTB of the
microvasculature of early, less mature and smaller malig-
nant brain tumor colonies does not explain why small
molecule chemotherapy drugs do not accumulate to effec-
tive concentrations within the extravascular compartment
of early, less mature and smaller malignant brain tumor
colonies, whether primary or metastatic.
Significance of the luminal glycocalyx layer of the 
BBTB of malignant brain tumor 
microvasculature
The well-defined physiologic upper limit of pore size in
the BBTB of 12 nm would be attributable to the presence
of a luminal glycocalyx layer overlaying the anatomic
defects within the BBTB. Since the fibrous matrix of the
glycocalyx overlaying endothelial barriers may be several
hundred nanometers thick [96-100], it would be the
"nanofilter" that serves as the main point of resistance to
the transvascular passage of spherical particles larger than
12 nm in diameter across the BBTB. Therefore, in the
physiologic state in vivo, the presence of the glycocalyx
would render the underlying endothelial cells of the BBTB
inaccessible to the transvascular passage of liposomes,
viruses, bacteria, or cells, unless the glycocalyx was
stretched, degraded, or disrupted in some manner [101-
107]. Furthermore, the glycocalyx layer would also be
expected to offer considerable resistance to the transvascu-
lar passage of non-spherical particles with sizes at the cusp
of the physiologic upper limit of pore size including mon-
oclonal antibodies (immunoglobulin G, IgG), which
have sizes of approximately 11 nm based on the calcula-
tion of antibody diffusion coefficients in viscous flu-
ids[108]. The 12 nm physiologic upper limit of pore size
Synthesis of gadolinium (Gd)-diethyltriaminepentaacetic acid (DTPA) conjugated polyamidoamine (PAMAM) dendrimers and  images of higher generation (G) Gd-dendrimers with annular dark-field scanning transmission electron microscopy Figure 1
Synthesis of gadolinium (Gd)-diethyltriaminepentaacetic acid (DTPA) conjugated polyamidoamine (PAMAM) 
dendrimers and images of higher generation (G) Gd-dendrimers with annular dark-field scanning transmission 
electron microscopy. A) Illustrations of naked PAMAM dendrimer generations from the ethylenediamine core (G0) to gen-
eration 3 (G3). The exterior of naked PAMAM dendrimers is positively charged due to the presence of terminal amine groups. 
The number of terminal amine groups doubles with each successive generation. B) Synthetic scheme for the production of Gd-
DTPA conjugated PAMAM dendrimers. The conjugation of Gd-DTPA (charge -2) to the terminal amine groups neutralizes the 
positive charge on the dendrimer exterior. C) Annular dark-field scanning transmission electron microscopy images of Gd-G5, 
Gd-G6, Gd-G7, and Gd-G8 dendrimers adsorbed onto an ultrathin carbon support film. The average diameter of sixty Gd-G7 
dendrimers is 11.0 ± 0.7 nm and that of sixty Gd-G8 dendrimers is 13.3 ± 1.4 nm (mean ± standard deviation). Scale bar = 20 
nm. Adapted from reference[73].Journal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
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is the likely reason why monoclonal antibody-based sys-
temic chemotherapy has not been effective at treating
malignant solid tumors[109].
Nanoparticle blood half-life and particle 
accumulation within individual brain tumor cells
With dynamic-contrast enhanced MRI we have character-
ized the relationship between Gd-dendrimer blood half-
life and transvascular extravasation across the BBTB of RG-
2 rodent malignant gliomas. Based on our findings, it is
evident that spherical nanoparticles ranging between 7
nm an 10 nm in diameter maintain peak blood concentra-
tions for several hours and are sufficiently smaller than
the 12 nm physiologic upper limit of pore size in the BBTB
to accumulate to effective concentrations within individ-
ual brain tumor cells[73,74]. For spherical particles that
are smaller than 6 nm in diameter, the distribution of par-
ticles within the extravascular compartment of tumor tis-
sue becomes more focal as particle size increases, since
these particles maintain peak blood concentrations for
only minutes[73]. However, for spherical particles that
range between 7 nm and 10 nm in diameter, the distribu-
tion of particles within the extravascular compartment of
tumor tissue is widespread, irrespective of particle size,
since these particles maintain peak blood concentrations
for several hours[73,74].
Spherical particles smaller than 6 nm in diameter (MW
less than 40 to 50 kDa)[88,110-112], which is the size
range of Gd-G1 through Gd-G4 dendrimers, possess rela-
tively short blood half-lives[73], and therefore, maintain
peak blood concentrations for only minutes (Figure
3)[73], as these particles are small enough to be efficiently
filtered by the kidney glomeruli[113]. As such, particles
smaller than 6 nm only remain temporarily within the
extravascular compartment of tumor tissue (Figure 2, rows
1 through 5)[73], which would not be sufficient time for
particles to accumulate to therapeutic concentrations
Dynamic contrast-enhanced MRI-based Gd concentration maps of Gd-dendrimer distribution within large and small RG-2  rodent gliomas over time Figure 2
Dynamic contrast-enhanced MRI-based Gd concentration maps of Gd-dendrimer distribution within large and 
small RG-2 rodent gliomas over time. A) Large RG-2 gliomas. Gd-G1 thorough Gd-G7 dendrimers extravasate across 
the BBTB of the microvasculature of large RG-2 gliomas. After extravasating across the BBTB, Gd-G1 through Gd-G4 den-
drimers only remain temporarily within the extravascular compartment of tumor tissue, as these lower Gd-dendrimer genera-
tions maintain peak blood concentrations for only a few minutes. The Gd-G5 through Gd-G7 dendrimers accumulate over 
time within the extravascular compartment of tumor tissue, as these generations maintain peak blood concentrations for sev-
eral hours. The Gd-G8 dendrimers remain intravascular, since Gd-G8 dendrimers are larger than the physiologic upper limit of 
pore size in the BBTB of large RG-2 gliomas. RG-2 glioma volumes (mm3): Gd-G1, 104; Gd-G2, 94; Gd-G3, 94; lowly conju-
gated (LC) Gd-G4, 162; Gd-G4, 200; Gd-G5, 230; Gd-G6, 201; Gd-G7, 170; Gd-G8, 289. B) Small RG-2 gliomas. Gd-G1 thor-
ough Gd-G6 dendrimers extravasate across the BBTB of the microvasculature of small RG-2 gliomas. Since small RG-2 gliomas 
are less vascular than large RG-2 gliomas, there is a relative lack of accumulation of the lower Gd-dendrimer generations in the 
extravascular compartment of small RG-2 gliomas as compared to large RG-2 gliomas (panel A). This is especially evident in 
the case of Gd-G1 dendrimers, which maintain peak blood concentrations for the shortest time period of all the Gd-dendrimer 
generations. Gd-G5 and Gd-G6 dendrimers accumulate over time within the extravascular compartment of even the small RG-
2 gliomas, since these generations maintain peak blood concentrations fro several hours and are smaller than the physiologic 
upper limit of pore size in the BBTB. Both Gd-G7 and Gd-G8 dendrimers remain intravascular in small RG-2 gliomas, since 
both Gd-G7 and Gd-G8 dendrimers are larger than the physiologic upper limit of pore size in the BBTB of small RG-2 gliomas. 
RG-2 glioma volumes (mm3): Gd-G1, 27; Gd-G2, 28; Gd-G3, 19; LC Gd-G4, 24; Gd-G4, 17; Gd-G5, 18; Gd-G6, 22; Gd-G7, 24; 
Gd-G8, 107. Respective Gd-dendrimer generations administered intravenously over 1 minute at a Gd dose of 0.09 mmol Gd/
kg animal body weight. Scale ranges from 0 mM [Gd] to 0.1 mM [Gd]. Adapted from reference[73].Journal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
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within individual brain tumor cells. The blood half-life of
small molecule chemotherapy drugs would be even
shorter than that of the smallest Gd-dendrimer, the Gd-
G1 dendrimer (Figure 2, row 1)[73]. Therefore, the short
blood half-life of small molecule chemotherapy drugs
would be the primary reason why these small drugs do
not accumulate to therapeutic concentrations within indi-
vidual brain tumor cells after extravasating across the
porous BBTB of malignant brain tumor microvasculature.
Spherical particles greater than 7 nm in diameter (MW
greater than 70 to 80 kDa)[88,110-112], which is the size
range of Gd-G5 through Gd-G8 dendrimers, possess rela-
tively long particle blood half-lives[74], and therefore,
maintain peak blood concentrations for several hours
(Figure 3)[73,74], as these particles are too large to be fil-
tered by the kidney glomeruli. Particles ranging between 7
nm and 10 nm in diameter, those being Gd-G5 and Gd-
G6 dendrimers, slowly accumulate over 2 hours within
the extravascular compartment of even small RG-2 malig-
nant gliomas (Figure 2, rows 6 and 7)[73]. Due to the pro-
longed residence time of particles within the extravascular
compartment of tumor tissue, there is significant endocy-
tosis of particles into individual RG-2 glioma cells, which
is evident on fluorescence microscopy of tumor tissue har-
vested 2 hours following the intravenous administration
of rhodamine B dye conjugated Gd-G5 dendrimers (Fig-
ure 4, panel D)[73]. This finding indicates that spherical
nanoparticles ranging between 7 nm and 10 nm in diam-
eter can be used to deliver therapeutic concentrations of
small molecule chemotherapy drugs across the BBTB and
into individual malignant glioma cells. Furthermore, with
spherical particles in the 7 to 10 nm size range, it would
be possible to deliver therapeutic concentrations of small
molecule chemotherapy drugs across the BBTB of the
microvasculature of early, less mature and smaller brain
tumor colonies (Figure 2, panel B, rows 6 and 7), even
though these smaller tumors are less vascular than late,
more mature and larger malignant brain
tumors[59,73,90,91,114,115].
Issue of positive charge on the nanoparticle 
exterior
Small molecules and peptides with significant focal posi-
tive charges[116,117] can disrupt the luminal glycocalyx
layer, which is a polysaccharide matrix bearing an overall
negative charge[96]. When positively charged small mol-
ecules are attached to the exterior of nanoparticles with
long blood half-lives, the prolonged exposure of the cati-
onic particle surface to the glycocalyx can result in its sig-
nificant disruption[116,118]. Prior to our recent studies
on the physiologic upper limit of the pore size within the
BBTB of malignant brain tumors and the blood-tumor
barrier (BTB) of malignant peripheral tumors[73,74], the
pore size within the BBTB and BTB had been probed by
intravital fluorescence microscopy 24 hours following the
intravenous infusion of cationic liposomes and micro-
spheres labeled on the exterior with rhodamine B
dye[116,119,120]. Since, in these prior studies, the intra-
vital fluorescence microscopy of particle extravasation
across the BBTB and BTB was performed 24 hours follow-
ing the intravenous infusion of cationic nanoparti-
cles[119,120], it is to be expected that the measured
physiologic pore sizes with this approach would approxi-
mate the sizes of anatomic defects underlying the glycoca-
lyx[85], as 24 hours would be sufficient time for cationic
nanoparticles to completely disrupt the glycocalyx and
expose the underlying anatomic defects within the respec-
tive tumor barriers.
The positive charge on exterior of the naked PAMAM den-
drimer generations is neutralized by the conjugation of
Gd-DTPA (charge -2) to a significant proportion of the ter-
minal amines. Therefore, intravenously administered Gd-
Steady-state blood concentrations of successively higher gen- eration Gd-dendrimers over time in rodents Figure 3
Steady-state blood concentrations of successively 
higher generation Gd-dendrimers over time in 
rodents. Gd-G1 dendrimers (MW 6 kDa), Gd-G2 dendrim-
ers (MW 11 kDa), Gd-G3 dendrimers (MW 19 kDa), lowly 
conjugated (LC) Gd-G4 dendrimers (MW 25 kDa), and 
standard Gd-G4 dendrimers (MW 40 kDa) maintain peak 
blood concentrations for only a few minutes. Gd-G5 den-
drimers (MW 80 kDa) maintain peak blood concentrations 
for over 2 hours. Gd-G6 dendrimers (MW 130 kDa), Gd-G7 
dendrimers (MW 330 kDa), and Gd-G8 dendrimers (MW 
597 kDa) also maintain peak blood concentrations for over 2 
hours similar to those of Gd-G5 dendrimers (concentration 
profiles not shown for purposes of figure clarity). Respective 
Gd-dendrimer generations administered intravenously over 
1 minute at a Gd dose of 0.09 mmol Gd/kg animal body 
weight. Blood concentrations of Gd-dendrimers over time 
measured in the superior sagittal sinus. Gd-G1 (n = 4), Gd-
G2 (n = 6), Gd-G3 (n = 6), lowly conjugated (LC) Gd-G4 (n 
= 4), Gd-G4 (n = 6), Gd-G5 (n = 6), Gd-G6 (n = 5), Gd-G7 
(n = 5), and Gd-G8 (n = 6). Error bars represent standard 
deviations. Adapted from reference[73].Journal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
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DTPA conjugated dendrimer generations do not disrupt
the glycocalyx overlaying the already porous BBTB and the
normally non-porous BBB. However, when rhodamine B
dye is conjugated to Gd-dendrimer terminal amines this
positively charged molecule protrudes above the nega-
tively charged Gd-DTPA moieties and re-introduces posi-
tive charge to the particle exterior, which results in
positive charge-induced disruption of the glycocalyx of
the already porous BBTB and the normally non-porous
BBB. The disruption of the glycocalyx overlaying the
already porous BBTB results in enhanced extravasation of
rhodamine B conjugated Gd-G5 dendrimers across the
BBTB and in some minimal extravasation of rhodamine B
conjugated Gd-G8 dendrimers across the BBTB, which is
evident in vivo on dynamic contrast-enhanced MRI 5 to 10
minutes following the intravenous infusion of the respec-
tive rhodamine B conjugated Gd-dendrimer genera-
tions(Figure 4, panel C)[73]. It is also evident ex vivo on
fluorescence microscopy of RG-2 glioma specimens har-
vested at 2 hours following intravenous infusion of the
respective rhodamine B conjugated Gd-dendrimer gener-
ations (Figure 4, panels D and E)[73]. This finding is con-
sistent with the greater exposure of underlying pre-
existent anatomic defects in the BBTB and a slight increase
in the physiologic upper limit of pore size in the BBTB due
to positive charge-induced toxicity to the glycocalyx.
The disruption of the glycocalyx overlaying the normally
non-porous BBB results in some non-selective minimal
extravasation of both rhodamine B conjugated Gd-G5 and
rhodamine B conjugated Gd-G8 dendrimers across the
BBB, which is evident in vivo on dynamic contrast-
enhanced MRI 30 to 45 minutes following the intrave-
nous infusion of the respective rhodamine B conjugated
Gd-dendrimer generations[73]. It is also evident ex vivo on
fluorescence microscopy of the normal brain tissue sur-
rounding RG-2 glioma tumor tissue (Figure 4, panels D
and E)[73]. This finding is consistent with the formation
of new anatomic defects within and between endothelial
cells of the BBB following disruption of the overlaying gly-
cocalyx. On the basis of our recent findings[73,74], in the
context of what has been previously
reported[106,107,121], it is evident that the presence of
positive charge on the nanoparticle exterior enhances the
transvascular extravasation of particles across pathologic
tumor barriers, and also across normal endothelial barri-
ers, by positive charge-induced toxicity to the luminal gly-
cocalyx layer.
The prototype of an imageable nanoparticle 
bearing chemotherapy within the 7 to 10 nm size 
range: The Gd-G5-doxorubicin dendrimer
Based on our finding that spherical nanoparticles ranging
between 7 nm and 10 nm in diameter effectively traverse
pores within the BBTB and accumulate to high concentra-
tions within individual brain tumor cells, an imageable
nanoparticle bearing chemotherapy within the 7 to 10 nm
size range, the Gd-G5-doxorubicin dendrimer, has been
developed (Figure 5, panel A). The Gd-G5-doxorubicin
dendrimer has been visualized in vitro with annular dark-
field scanning electron microscopy (Figure 5, panel B).
Gd-DTPA was conjugated to approximately 50% of the
terminal amines and doxorubicin to approximately 8% of
the terminal amines of a G5 PAMAM dendrimer (Table 1),
which yielded the optimal ratio of contrast agent-to-drug
for dynamic contrast-enhanced MRI and systemic chemo-
therapy, respectively.
The doxorubicin was conjugated to the Gd-G5 dendrimer
terminal amines via a pH-sensitive hydrazone bond that
is stable at the physiologic pH of 7.4, and labile at the
acidic pH of 5.5 in lysosomal compartments [122-125].
The functionality of the pH-sensitive hydrazone bond was
verified  in vitro with fluorescence microscopy, which
showed that there is accumulation of free doxorubicin in
RG-2 glioma cell nuclei following the incubation of gli-
oma cells for 4 hours in media containing Gd-G5-doxoru-
bicin dendrimers (Figure 5, panel C). The relative stability
of the hydrazone bond at physiologic pH would limit
doxorubicin release in the systemic blood circulation and
minimize any systemic toxicity associated with free drug
release in the bloodstream, prior to particle extravasation
across the BBTB. It would be expected that there would be
limited free drug release within the extravascular extracel-
lular compartment of tumor tissue after particle extravasa-
tion across the BBTB, since the extravascular extracellular
compartment is significantly less acidotic than the intrac-
ellular lysosomal compartments of cells[124,126]. Fur-
thermore, there would be rapid doxorubicin release
following particle endocytosis into tumor cell lysosomal
compartments, which would enable the free doxorubicin
to traverse the nuclear pores and interact with the DNA.
Most small molecule chemotherapy drugs act within the
cell nucleus, which necessitates that free drug be released
into the tumor cell cytoplasm, which would not be possi-
ble to accomplish with spherical nanoparticles larger than
Gd-G2 dendrimers, as particles of sizes larger than Gd-G2
dendrimers do not appear to effectively traverse nuclear
pores (Figure 4, panel B)[73].
The cytotoxicity of the Gd-G5-doxorubicin dendrimer was
verified in vitro with RG-2 glioma cell survival measured
by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) assay[127]. The Gd-G5-doxoru-
bicin dendrimer was intravenously bolused over 2
minutes to orthotopic RG-2 glioma bearing rodents at a
dose of 8 mg/kg with respect to doxorubicin. On dynamic
contrast-enhanced MRI over 1 hour, it was evident that
the Gd-G5-doxorubicin dendrimer extravasates across the
BBTB and accumulates within the extravascular compart-Journal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
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Synthesis of rhodamine B dye (RB) conjugated Gd-dendrimers and fluorescence microscopy of rhodamine B conjugated Gd- dendrimer uptake in cultured RG-2 glioma cells versus in RG-2 glioma cells of harvested RG-2 glioma tumor specimens Figure 4
Synthesis of rhodamine B dye (RB) conjugated Gd-dendrimers and fluorescence microscopy of rhodamine B 
conjugated Gd-dendrimer uptake in cultured RG-2 glioma cells versus in RG-2 glioma cells of harvested RG-2 
glioma tumor specimens. A) Synthetic scheme for production of rhodamine B dye conjugated Gd-dendrimers. Rhodamine 
B and DTPA are conjugated to the naked dendrimer terminal amines via stable covalent bonds. In functionalized dendrimers, 
approximately 35% of the terminal amines are occupied by Gd-DTPA, and approximately 7% of the terminal amines are occu-
pied by rhodamine B. B) In vitro fluorescence microscopy of cultured RG-2 glioma cells incubated for 4 hours in media contain-
ing either rhodamine B conjugated Gd-G2 dendrimers (left), rhodamine B conjugated Gd-G5 dendrimers (middle), or 
rhodamine B conjugated Gd-G8 dendrimers (right) at a concentration of 7.2 μM with respect to rhodamine B. Scale bars = 20 
μm. Rhodamine B conjugated Gd-G2 dendrimers enter RG-2 glioma cells, and in some cases, the cell nuclei (left). Rhodamine 
B conjugated Gd-G5 dendrimers (middle) and rhodamine B conjugated Gd-G8 dendrimers (right) enter the cytoplasm of RG-2 
glioma cells, but do not localize within the nuclei. C) Dynamic contrast-enhanced MRI-based Gd concentration curves of RG-2 
glioma tumor tissue over time following the intravenous bolus of 0.06 mmol Gd/kg of rhodamine B conjugated Gd-G5 den-
drimers (n = 6) and rhodamine B conjugated Gd-G8 dendrimers (n = 2). There is substantial extravasation of rhodamine B 
conjugated Gd-G5 dendrimers across the BBTB, which is more pronounced than that of Gd-G5 dendrimers across the BBTB. 
There is also some extravasation of rhodamine B conjugated Gd-G8 dendrimers across the BBTB, which is not the case for 
Gd-G8 dendrimers. D) Ex vivo low power fluorescence microscopy of RG-2 glioma tumor and surrounding brain tissue har-
vested at 2 hours following the intravenous bolus of rhodamine B conjugated Gd-G5 dendrimers. There is substantial accumu-
lation of rhodamine B conjugated Gd-G5 dendrimers within tumor tissue, and some in surrounding normal brain tissue (left, T 
= tumor, N = normal, scale bar = 100 μm). High power image of RG-glioma tumor shows subcellular localization of rhodamine 
B conjugated Gd-G5 dendrimers within individual RG-2 malignant glioma cells (upper right, scale bar = 20 μm). H&E stain of 
tumor and surrounding brain (lower right, scale bar = 100 μm). Tumor volume is 31 mm3. E) Ex vivo low power fluorescence 
microscopy of RG-2 glioma tumor and surrounding brain tissue harvested at 2 hours following the intravenous bolus of rhod-
amine B conjugated Gd-G8 dendrimers. There is some minimal accumulation of rhodamine B conjugated Gd-G8 dendrimers 
within brain tumor tissue (left, T = tumor, N = normal, scale bar = 100 μm). High power confirms there is some minimal sub-
cellular localization of rhodamine B conjugated Gd-G8 dendrimers within individual RG-2 glioma cells (upper right, scale bar = 
20 μm). H&E stain of tumor and surrounding brain (lower right, scale bar = 100 μm). Tumor volume is 30 mm3. Rhodamine B 
conjugated Gd-G5 dendrimers and rhodamine B conjugated Gd-G8 dendrimers administered intravenously over 1 minute at a 
Gd dose of 0.06 mmol Gd/kg animal body weight. Adapted from reference[73].Journal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
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The prototype of an imageable nanoparticle bearing chemotherapy within the 7 to 10 nm size range: The Gd-G5-doxorubicin  dendrimer Figure 5
The prototype of an imageable nanoparticle bearing chemotherapy within the 7 to 10 nm size range: The Gd-
G5-doxorubicin dendrimer. A) An illustration of the Gd-G5-doxorubicin dendrimer. Doxorubicin is conjugated to the den-
drimer terminal amines by a pH-sensitive hydrazone bond, which facilitates the rapid release of doxorubicin following particle 
endocytosis into brain tumor cell lysosomal compartments. B) Annular dark-field scanning transmission electron microscopy 
image of Gd-G5-doxorubicin dendrimers. C) In vitro fluorescence microscopy of cultured RG-2 glioma cells incubated for 4 
hours in media containing Gd-G5-doxorubicin dendrimers at a 600 nM concentration. The red fluorescence in the cytoplasm 
represents Gd-G5-doxorubicin dendrimers within the cytoplasm of RG-2 glioma cells. The red fluorescence within the RG-2 
cell nuclei represents free doxorubicin that has been released from the Gd-G5-doxorubicn dendrimers following cleavage of 
the hydrazone bond, since particles larger than Gd-G2 dendrimers are too large to pass through the nuclear pores. D) T2-
weighted anatomic scan image and T1-weighted dynamic contrast-enhanced MRI scan Gd concentration map images at various 
time points up to 60 minutes following Gd-G5-doxorubicn dendrimer infusion. The Gd-G5-doxorubicin dendrimer was admin-
istered intravenously over 2 minutes at a Gd dose of 0.09 mmol Gd/kg, which is equivalent to a doxorubicin dose of 8 mg/kg. 
The T2-weighted anatomic scan image shows the location of the RG-2 glioma in the right caudate of rat brain, which has a 
tumor volume of 16 mm3. The first T1-weighted dynamic contrast-enhanced MRI scan image displays the lack of contrast 
enhancement prior to Gd-G5 doxorubicin dendrimer infusion. The second T1-weighted dynamic contrast-enhanced MRI scan 
image confirms contrast enhancement in the vasculature immediately after Gd-G5-doxorubicin dendrimer infusion. The third 
T1-weighted dynamic contrast-enhanced MRI scan image shows that at 60 minutes following the Gd-G5-doxorubicin dendrimer 
infusion there is significant Gd-G5-doxorubicin accumulation within the RG-2 glioma tumor extravascular extracellular space, 
which confirms that the Gd-G5-doxorubicin dendrimer has extravasated slowly across the BBTB over timer due to its long 
blood half-life. The white arrow highlights that there is positive contrast enhancement of normal brain tissue, which indicates 
that there is extravasation of the Gd-G5-doxorubicin dendrimer across the normal BBB. E) Percent change in RG-2 malignant 
glioma volume within 24 hours. One group of orthotopic RG-2 glioma bearing animals received one intravenous 8 mg/kg dose 
of Gd-G5-doxorubicin dendrimer with respect to doxorubicin (n = 7), and the other group of glioma bearing animals received 
one 8 mg/kg dose of free doxorubicin (n = 7). Pre-treatment whole RG-2 glioma tumor volumes calculated based on initial T2-
weighted anatomic scans acquired immediately prior to agent administration, and post-treatment whole RG-2 glioma tumor 
volumes calculated based on repeat T2-weighted anatomic scans acquired within 22 ± 2 hours for the Gd-G5-doxorubicin 
group and 24 ± 1 hour for the free doxorubicin group. One dose of the Gd-G5-doxorubicin dendrimer is significantly more 
effective than one dose of free doxorubicin at inhibiting the growth of orthotopic RG-2 malignant gliomas for approximately 24 
hours. Student's two-tailed paired t-test p value < 0.0008.Journal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
Page 10 of 14
(page number not for citation purposes)
ment of brain tumor tissue over time (Figure 5, panel D).
There was, however, also some transvascular extravasation
of the Gd-G5-doxorubicin dendrimer across the normal
BBB and non-selective accumulation of Gd-G5-doxoru-
bicin dendrimer in normal brain tissue (Figure 5, panel D
arrow), which would be attributable to the re-introduc-
tion of focal positive charge to the Gd-G5 dendrimer exte-
rior due to the attachment of doxorubicin, which is a
cationic drug[128]. Despite this drawback, one 8 mg/kg
dose of Gd-G5-doxorubicin dendrimer with respect to
doxorubicin was found to be significantly more effective
than one 8 mg/kg dose of free doxorubicin at inhibiting
the growth of orthotopic RG-2 malignant gliomas for
approximately 24 hours (Figure 5, panel E). The short-
term efficacy of this approach stems from the accumula-
tion of small molecule chemotherapy to therapeutic con-
centrations directly within individual brain tumor cells.
The long-term efficacy of this approach will need to be
evaluated in various animal malignant glioma mod-
els[129,130], prior to clinical translation.
Therapeutic implications and future perspective
The Gd-G5-doxorubicin dendrimer, being a nanoparticle
bearing chemotherapy within the 7 nm to 10 nm size
range, delivers therapeutic concentrations of doxorubicin
across the porous BBTB of malignant brain tumors into
individual tumor cells. Doxorubicin attachment to the
Gd-G5-doxorubicin dendrimer via pH-sensitive hydra-
zone bonds facilitates rapid doxorubicin release within
the brain tumor cell lysosomal compartments and the
accumulation of released doxorubicin within tumor cell
nuclei. The short-term efficacy of the Gd-G5-doxorubicin
dendrimer in regressing RG-2 malignant gliomas stems
from the effective transvascular delivery of doxorubicin
across the BBTB into individual brain tumor cells. The
attachment of doxorubicin to the Gd-G5 dendrimer exte-
rior, however, re-introduces positive charge to Gd-G5-
dendrimer exterior, since the positively charged doxoru-
bicin molecules protrude above the negatively charged
Gd-DTPA molecules. The presence of positive charge on
the Gd-G5-doxorubicin dendrimer exterior is toxic to the
luminal glycocalyx layer and results in non-selective accu-
mulation of the Gd-G5-doxorubicin dendrimer in normal
brain tissue. Therefore, in the future, cationic small mole-
cule chemotherapy drugs will need to be conjugated by
hydrazone bonds closer to the particle interior, which
would minimize the re-introduction of positive charge on
the particle exterior. Furthermore, in the future, it may
also be advantageous to use naked half generation
PAMAM dendrimers (i.e. G5.5) as substrates for conjuga-
tion of cationic molecules, since these PAMAM dendrimer
generations are anionic. Other types of biocompatible
dendrimers, for example, those that are amino acid-based,
would also be appropriate substrates for functionaliza-
tion, provided there is no net positive charge on the func-
tionalized particle surface.
Boron neutron capture therapy (BNCT)[131] has been rel-
atively ineffective in the treatment of malignant brain
tumors since it has not been possible to deliver high con-
centrations of 10boron (10B) into individual brain tumor
cells. Local chemotherapy delivery methodologies such as
convection-enhanced delivery (CED)[132,133] only
deliver high concentrations of 10B within a few millime-
ters of the delivery site[134]. Intravenously administered
imageable dendrimers within the 7 nm to 10 nm size
range bearing polyhedral borane cages[135] could be
used to deliver therapeutic concentrations of 10B to indi-
vidual brain tumor cells. This is has not been possible to
accomplish with: (1) the boronated G4 dendrimer-epi-
dermal growth factor (BD-EGF) particle, as this particle
has a molecular weight of approximately 35 kDa[136],
which would be consistent with a short blood half-life,
and (2) the boronated monoclonal antibody[137], as the
size of this antibody is close to the 12 nm physiological
upper limit of pore size and the particle shape is non-
spherical[108]. Spherical nanoparticles within the 7 nm
to 10 nm size range bearing polyhedral borane cages
would be able to deliver effective concentrations of 10B to
individual brain tumor cells.
The premise underlying the future, successful, clinical
translation of the proposed strategy is that the BBTB of
malignant brain tumor microvasculature remain some-
what porous, which will necessitate that corticosteroid
and VEGF inhibitor treatments be held to a minimum
Table 1: Properties of the Gd-G5-doxorubicin dendrimer
PAMAM 
dendrimer 
generation 
(G)
Terminal amines (#) Naked 
dendrimer 
molecular weight 
(kDa)
Gd-G5-doxorubicin 
dendrimer molecular 
weight (kDa)
Gd-DTPA 
conjugation (%)
Doxorubicin 
conjugation (%)
Molar relaxivity 
(mM-1s-1)
G5 128 29# 85‡ 48.1 7.8 10.1&
# molecular weight of naked PAMAM dendrimer obtained from Dendritech, Inc.
‡molecular weight measured by MALDI-TOF mass spectrometry
&molar relaxivity of Gd-DTPA measured to be 4.1 mM-1s-1Journal of Translational Medicine 2009, 7:77 http://www.translational-medicine.com/content/7/1/77
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prior to and during the application of the proposed strat-
egy, as it is known that these treatments significantly
decrease the porosity of the BBTB. In summary, spherical
nanoparticles ranging between 7 nm and 10 nm in diam-
eter maintain peak blood concentrations for several hours
and are sufficiently smaller than the 12 nm physiologic
upper limit of pore size in the BBTB to accumulate to ther-
apeutic concentrations within individual brain tumor
cells. Therefore, nanoparticles bearing chemotherapy that
are within this 7 to 10 nm size range can be used to deliver
therapeutic concentrations of small molecule chemother-
apy drugs across the BBTB into individual brain tumor
cells.
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